1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Pre-proposals due May 27, 2026, 5 p.m. ET — matches stored deadline of 2026-05-27. Full proposals (invited) due September 15, 2026.
"Targets to Therapies: Aggregation and Synuclein Biology Target Validation" is currently closed and not accepting applications.
Targets to Therapies: Aggregation and Synuclein Biology Target Validation is sponsored by The Michael J. Fox Foundation for Parkinson's Research (MJFF). This program seeks to build a robust evidence base for aggregation and synuclein biology targets with high potential relevance to Parkinson's disease.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Targets to Therapies: Aggregation and Synuclein Biology Target Validation | Parkinson's Disease Search for topics, articles, videos, research, etc...
Hit enter to search or ESC to close Targets to Therapies: Aggregation and Synuclein Biology Target Validation Targets to Therapies: Aggregation and Synuclein Biology Target Validation The Targets to Therapies Program seeks to build a robust evidence base for aggregation and synuclein biology targets with high potential relevance to Parkinson’s disease.
Funding will support projects to clarify human relevance, define mechanism in Parkinson's-relevant contexts, establish target engagement or develop enabling tools and assays.
Target modulation in cell and animal models to determine efficacy on Parkinson's phenotypes Generate evidence linking target biology to Parkinson's patient samples Clarifying the therapeutic mechanism of action Identify and test biomarkers to aid preclinical therapeutic validation and patient stratification Biological safety through animal model characterization When considering proposals submitted to this program, MJFF prioritizes those that: Directly address known target gaps (e.g., human modulation, biomarker linkage, mechanism in alpha-synuclein biology and related Parkinson's pathology) Generate reproducible, translatable data that advances the target toward a therapeutic decision point MJFF will not consider proposals focused on the following: Broad discovery without a defined target/mechanism Therapeutic development programs not directly tied to target validation Learn more about the Targets to Therapies Initiative at https://www.
michaeljfox. org/targets-therapies-initiative . Please note that MJFF has an Open Science Policy which governs research outputs (such as preprints, journal articles, data, code, and software) resulting from MJFF-funded work.
The Open Science Policy applies to this funding program and includes specific rules, timing, and format for the return of those research outputs and requires them to be shared openly, to be free to access, and with persistent identifiers. Please contact openscience@michaeljfox. org for questions about the Open Science Policy.
Here. Until Parkinson's isn't. Help us speed a cure for the 6 million people worldwide living with Parkinson's.
Join our email list to get the latest news and resources directly to your inbox. Connection to Parkinson's Immediate family member has PD Immediate family member had PD Extended family member or friend has PD Extended family member or friend had PD I am a researcher, clinician or work with the PD community What Year Were You Diagnosed with PD?
According to the current listing, eligibility includes: Researchers working on aggregation and synuclein biology in Parkinson's disease contexts; requires grant portal account and pre-proposal submission. Confirm the full requirements in the official notice before applying.
The current listing shows $250,000 - $2,000,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was May 27, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Targets to Therapies: Aggregation and Synuclein Biology Target Validation is funded by The Michael J. Fox Foundation for Parkinson's Research (MJFF). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.